Changes in the basis of vitreous body in case of uveitis treated by adalimumab
DOI:
https://doi.org/10.31288/oftalmolzh201566467Keywords:
uveitis, Adalimumab, changes in the basis of vitreous bodyAbstract
Objective of the research is to study the dynamics of changes in the basis of vitreous body in case of uveitis treated by Adalimumab.
Material and methods. 5 year old patient S. with recurrent anterior uveitis on the background of juvenile arthritis was observed.
Results. After 4 months of treatment by Adalimumab (20 mg 1 time every 2 weeks combined with methotrexate 10 mg 1 time a week) an exudate has reabsorbed in the prebasal sections of the vitreous body, and after seven months - in the basal ones. During the year no uveitis exacerbations were checked.
Conclusions. When uveitis is treated by Adalimumab the exudate is reabsorbed more slowly in basal sections of the vitreous body. Usage of Adalimumab in the treatment of uveitis is effective and in combination with methotrexate helps to prevent relapses.
References
Panchenko NV, Samofalova MN, Borisova LI. [Proinflammatory cytokines in patients with uveitis complicated by optic neuritis]. Tavricheskii medico-biol. Vestnik. Proceedings of scientific and practical conference with international participants "Azarovskii reading. Neuroophtalmology, pathology of the retina". Sudak, 2011. Tavricheskii medico-biol. vestnik. 2011; 14(4:2):398-399. Russian.
Aikawa NE. De Carvalho JF, Silva CA et al. Immunogenicity of anti-TNF a agents in autoimmune diseases. Clinic. Rev. Allerg. Immunol. 2010;38:2-3:82-89. https://doi.org/10.1007/s12016-009-8140-3
Beister S, Deuter C, Michels H. et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol. 2007;91:319-324.https://doi.org/10.1136/bjo.2006.103721
Bou R, Iglesias E, Ant?n J. Treatment of uveitis associated with juvenile idiopathic arthritis. Curr. Rheumatol. Rep. 2014;16(8):437.https://doi.org/10.1007/s11926-014-0437-4
Chylack LT. The ocular manifestations of juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20(2):217-223.https://doi.org/10.1002/art.1780200214
Foster CS, Tufail F, Waheed NK et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol. 2003;121(4):437-440.https://doi.org/10.1001/archopht.121.4.437
Gallagher M, Quinones K, Cervantes-Casta?eda RA et al. Biological response modifier therapy for refractory childhood uveitis. Br. J. Ophthalmol. 2007;91(10):1341-1344.https://doi.org/10.1136/bjo.2007.124081
Guignard S, Gossec L, Salliot C et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in spondylarthropathy patients: a retrospective study. Ann. Rheum. Dis. 2006;65(12):1631-1634.https://doi.org/10.1136/ard.2006.052092
Guijo PV, Lacomba SM, Hernandez SM et al. Tumor necrosis factor alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr. Med. Res. Opin. 2004;20:155-157.https://doi.org/10.1185/030079903125002847
Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur. J. Ophthalmol. 2007;17(5):743-748.https://doi.org/10.1177/112067210701700509
Heinz C, Mingels A, Goebel C, Fuchsluger T, Heiligenhaus A. Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course. J. Rheumatol. 2008;35:1403-1407.
Kanski JJ. Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye (Lond). 1988;2:641-645.https://doi.org/10.1038/eye.1988.118
Kotaniemi K, S?il? H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin. Ophthalmol. 2011;5:1425-1429.https://doi.org/10.2147/OPTH.S23646
Lacomba SM, Mart?n MC, Galera GJM et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251-255.https://doi.org/10.1159/000055677
La Torre F, Cattalini M, Teruzzi B et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series. BMC Res. Notes. 2014;7:316.https://doi.org/10.1186/1756-0500-7-316
Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. In: Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. N. Engl. J. Med. 2008;359:810-820.
Ramanan AV, Dick AD, Benton D et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis. SYCAMORE Trial. 2014;15:14.https://doi.org/10.1186/1745-6215-15-14
Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, Silverman ED. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term follow-up study. Arthritis Rheum. 2007;56:647-657.https://doi.org/10.1002/art.22381
Semeraro F, Arcidiacono B, Nascimbeni G et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug. Des. Devel. Ther. 2014;24(8):341-348.https://doi.org/10.2147/DDDT.S54207
Simonini G, Taddio A, Cattalini M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. Hoboken. 2011;63(4):612-618.https://doi.org/10.1002/acr.20404
Tynj?l? P, Kotaniemi K, Lindahl P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology. Oxford. 2008;47(3):339-344.https://doi.org/10.1093/rheumatology/kem356
Vasquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006;149(4):572-575.https://doi.org/10.1016/j.jpeds.2006.04.058
Zulian F, Birolo C, Zannin ME. Treatment approach for juvenile idiopathic arthritis-related uveitis. In: Department of Pediatrics, University of Padova, Italy. Current Pediatrics. 2012;11(5):36-44.https://doi.org/10.15690/vsp.v11i5.426
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Н. В. Панченко, Т. А. Храмова, А. Ю. Литвищенко, Г. С. Саркисян, М. Н. Самофалова, Е. Н. Гончарь, М. В. Фрянцева
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
